KIMS Hospitals Signs 60-Year Lease for 2 Acres in Amaravati to Build 500-Bed Multi-Speciality Hospital

1 min read     Updated on 09 May 2026, 04:08 AM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Krishna Institute of Medical Sciences (KIMS Hospitals) has signed a 60-year lease for 2 acres of land in Amaravati, Andhra Pradesh, with APCRDA to develop a 500-bedded multi-speciality hospital. The facility will offer tertiary and quaternary care across specialties including Cardiology, Oncology, Neurosciences, and Organ Transplant, aiming to improve advanced healthcare access in the region.

powered bylight_fuzz_icon
39822681

*this image is generated using AI for illustrative purposes only.

Krishna Institute of Medical Sciences Limited (KIMS Hospitals) has entered into a long-term lease agreement for 2 acres of land in Amaravati, Andhra Pradesh, for a period of 60 years. The agreement has been executed with the Andhra Pradesh Capital Region Development Authority (APCRDA) and was disclosed to stock exchanges on 8th May, 2026, as a material event.

Key Details of the Lease Agreement

The following table outlines the key parameters of the lease agreement as disclosed by the company:

Parameter: Details
Land Area: 2 acres
Location: Amaravati, Andhra Pradesh
Lease Duration: 60 years
Lessor: Andhra Pradesh Capital Region Development Authority (APCRDA)
Proposed Facility: 500-bedded multi-speciality hospital

Proposed Hospital and Specialties

The proposed facility is described as a state-of-the-art 500-bedded multi-speciality hospital that will offer comprehensive tertiary and quaternary care. The hospital is planned to cover a wide range of medical specialties, as detailed below:

  • Cardiology
  • Oncology
  • Neurosciences
  • Gastroenterology
  • Orthopaedics
  • Mother & Child Care
  • Critical Care
  • Organ Transplant
  • Other key specialties

Healthcare Access in the Region

According to the company's disclosure, the proposed hospital aims to address a long-standing need for advanced healthcare infrastructure in the Amaravati region. The facility is expected to provide patients in Amaravati and surrounding districts of Andhra Pradesh with access to high-end clinical capabilities, reducing the need to travel to other metros for specialized medical care.

The disclosure was signed by Nagajayanthi J. R., Company Secretary and Compliance Officer of Krishna Institute of Medical Sciences Limited, and was submitted to both BSE and NSE on 8th May, 2026.

Historical Stock Returns for Krishna Institute of Medical Sciences

1 Day5 Days1 Month6 Months1 Year5 Years
+8.40%+16.67%+17.09%+6.83%+22.59%+290.11%

How will KIMS Hospitals finance the construction of the 500-bedded Amaravati facility, and what impact will this capital expenditure have on the company's debt profile and near-term earnings?

Could the Amaravati hospital project accelerate KIMS Hospitals' expansion into other emerging state capital cities, signaling a broader tier-2 city growth strategy?

How might the entry of a major tertiary care provider like KIMS into Amaravati affect the competitive landscape and patient referral patterns for existing regional hospitals in Andhra Pradesh?

Krishna Institute of Medical Sciences
View Company Insights
View All News
like17
dislike

Krishna Institute of Medical Sciences Schedules Board Meeting on May 15, 2026 to Approve Q4 and Full-Year FY26 Financial Results

1 min read     Updated on 06 May 2026, 11:25 AM
scanx
Reviewed by
Shriram SScanX News Team
AI Summary

Krishna Institute of Medical Sciences has notified stock exchanges of a Board of Directors meeting scheduled for May 15, 2026, to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The filing was made under Regulation 29(1) of SEBI (LODR) Regulations, 2015. The company's trading window has been closed since April 1, 2026, and will remain shut until 48 hours after the financial results are announced, applicable to all Directors, Officers, Designated Persons, and Connected Persons.

powered bylight_fuzz_icon
39592557

*this image is generated using AI for illustrative purposes only.

Krishna Institute of Medical Sciences has intimated stock exchanges of a forthcoming Board of Directors meeting scheduled for Friday, May 15, 2026. The notice, filed pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, states that the board will convene to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.

Board Meeting Details

The following key details have been disclosed in the regulatory filing:

Parameter: Details
Meeting Date: Friday, May 15, 2026
Purpose: Approval of audited Standalone & Consolidated financial results
Period Under Review: Quarter and year ended March 31, 2026
Regulatory Reference: Regulation 29(1) of SEBI (LODR) Regulations, 2015

Trading Window Closure

In accordance with the Company's Code of Conduct for the Prevention of Insider Trading, Krishna Institute of Medical Sciences has also disclosed the status of its trading window. The key details are as follows:

  • The trading window for dealing in the company's shares was closed with effect from Wednesday, April 1, 2026.
  • The trading window will remain closed until 48 hours after the announcement of the financial results for the quarter and financial year ended March 31, 2026.
  • This restriction applies to all Directors, Officers, Designated Persons, and Connected Persons of the company.

The regulatory intimation was signed by Nagajayanthi J.R, Company Secretary & Compliance Officer of Krishna Institute of Medical Sciences, and was dated May 06, 2026.

Historical Stock Returns for Krishna Institute of Medical Sciences

1 Day5 Days1 Month6 Months1 Year5 Years
+8.40%+16.67%+17.09%+6.83%+22.59%+290.11%

How might Krishna Institute of Medical Sciences' FY2026 annual revenue and profitability compare to its previous fiscal year, and what growth trajectory does this signal for the healthcare sector?

Will the board meeting on May 15, 2026 also consider dividend declarations or any capital allocation decisions alongside the financial results approval?

How could KIMS' FY2026 financial performance influence its expansion plans, particularly regarding new hospital acquisitions or greenfield projects in Tier-2 cities?

Krishna Institute of Medical Sciences
View Company Insights
View All News
like16
dislike

More News on Krishna Institute of Medical Sciences

1 Year Returns:+22.59%